These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8005960)

  • 21. Deferiprone for thalassaemia.
    Pippard MJ; Weatherall DJ
    Lancet; 2000 Oct; 356(9239):1444-5. PubMed ID: 11052617
    [No Abstract]   [Full Text] [Related]  

  • 22. Thalassemia treatment and prevention in Uva Province, Sri Lanka: a public opinion survey.
    Mudiyanse RM
    Hemoglobin; 2006; 30(2):275-89. PubMed ID: 16798653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Deferiprone: New insight.
    Piga A; Roggero S; Vinciguerra T; Sacchetti L; Gallo V; Longo F
    Ann N Y Acad Sci; 2005; 1054():169-74. PubMed ID: 16339662
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical studies on iron chelation in patients with thalassemia major.
    Freedman MH; Olivieri N; Benson L; Liu P; McClelland R; St Louis P; Templeton D; Koren G
    Haematologica; 1990; 75 Suppl 5():74-83. PubMed ID: 2086384
    [No Abstract]   [Full Text] [Related]  

  • 25. The pharmacokinetics and pharmacodynamics of the oral iron chelator deferiprone (L1) in relation to hemoglobin levels.
    Fassos FF; Klein J; Fernandes D; Matsui D; Olivieri NF; Koren G
    Int J Clin Pharmacol Ther; 1996 Jul; 34(7):288-92. PubMed ID: 8832304
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral iron chelators.
    Lancet; 1989 Oct; 2(8670):1016-7. PubMed ID: 2572743
    [No Abstract]   [Full Text] [Related]  

  • 27. [Long-term treatment of patients with transfusion hemosiderosis using oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1)].
    Goudsmit R
    Ned Tijdschr Geneeskd; 1991 Nov; 135(45):2133-6. PubMed ID: 1944690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined therapy with deferoxamine and deferiprone.
    Kattamis A
    Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Experience with the oral iron chelator deferiprone in transfusion-dependent children.
    Lucas GN; Perera BJ; Fonseka EA; De Silva DD; Fernandopulle M; Karunatilaka DH; Weerasinghe I
    Ceylon Med J; 2002 Dec; 47(4):119-21. PubMed ID: 12661341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents].
    Esposito L; Ferrara M; Ponte G
    Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759
    [No Abstract]   [Full Text] [Related]  

  • 31. Oral iron chelation with 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron loaded thalassemia patients.
    Olivieri NF; Matsui D; Liu PP; Blendis L; Cameron R; McClelland RA; Templeton DM; Koren G
    Bone Marrow Transplant; 1993; 12 Suppl 1():9-11. PubMed ID: 8374574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Posterior subcapsular opacity in two patients with thalassaemia major following deferiprone consumption.
    Mehdizadeh M; Nowroozzadeh MH
    Clin Exp Optom; 2009 Jul; 92(4):392-4. PubMed ID: 19515094
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety of oral iron chelator L1.
    Kontoghiorghes GJ; Nasseri-Sina P; Goddard JG; Barr JM; Nortey P; Sheppard LN
    Lancet; 1989 Aug; 2(8660):457-8. PubMed ID: 2569645
    [No Abstract]   [Full Text] [Related]  

  • 34. Febrile neutropenia and hemorrhagic stroke in a thalassemia major patient.
    Sheikh-Taha M; Koussa S; Inati A; Taher A
    Hemoglobin; 2007; 31(4):499-501. PubMed ID: 17994386
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term treatment with deferiprone in a L1 veteran.
    Meo A; Ruggeri A; La Rosa MA; Zanghì L; Kordes U; Fischer R
    Eur J Haematol; 2005 Jun; 74(6):523-5. PubMed ID: 15876257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of ICL670, a once-daily oral iron chelator in a phase III clinical trial of beta-thalassemia patients with transfusional iron overload.
    Galanello R
    Ann N Y Acad Sci; 2005; 1054():183-5. PubMed ID: 16339664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The safety, tolerability, and efficacy of a liquid formulation of deferiprone in young children with transfusional iron overload.
    ElAlfy MS; Sari TT; Lee CL; Tricta F; El-Beshlawy A
    J Pediatr Hematol Oncol; 2010 Nov; 32(8):601-5. PubMed ID: 20921906
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
    Kolnagou A; Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review.
    Delea TE; Edelsberg J; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Transfusion; 2007 Oct; 47(10):1919-29. PubMed ID: 17880620
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmaco/ferrokinetic-related pro-oxidant activity of deferiprone in beta-thalassemia.
    Jirasomprasert T; Morales NP; Limenta LM; Sirijaroonwong S; Yamanont P; Wilairat P; Fucharoen S; Chantharaksri U
    Free Radic Res; 2009 May; 43(5):485-91. PubMed ID: 19353420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.